KETAMINE IN DEPRESSION THERAPY (overview of modern data)


Cite item

Full Text

Abstract

Various aspects of the clinical use of ketamine for the treatment of depression, including mechanisms of its pharmacological and psychedelic effects, frequently used protocols and tolerability characteristics are presented in the brief literature overview. The purpose of the review is to expand the evidence base for making informed clinical decisions and improving the response to the treatment of depressive disorders.

About the authors

Mikhail L Zobin

Transformation therapy Centre Kindness

Email: dr.zobin@yandex.ru
85330 city of Kotor, Montenegro

References

  1. aan het Rot M., Collins K.A., Murrough J.W. et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression // Biological Psychiatry. 2010. Vol. 67. P. 139-145
  2. aan het Rot M., Zarate C., Charney D.S., Mathew S.J. Ketamine for depression: Where do we go from here? // Biological Psychiatry. 2012. Vol. 72[7]. P. 537-547
  3. Abdallah C.G., Adams T.G., Kelmendi B. et al. Ketamine’s mechanism of action: a path to rapid-acting antidepressants // Depress Anxiety. 2016 Aug. Vol. 33[8]. P. 689-697
  4. Abdallah C.G., Fasula M., Kelmendi B. et al. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting // J ECT 2012 Sep. Vol. 28[3]. P. 157-161
  5. Adida M., Kaladjian A., Fakra E. et al. [Co-occuring mood and substance use disorders] // Encephale. 2014 Dec. Vol. 40, Suppl. 3. P. S8-S13
  6. Ahnaou A., Huysmans H., Biermans R. at al. Ketamine: differential neurophysiological dynamics in functional networks in the rat brain // Transl Psychiatry. 2017 Sep 19. Vol. 7[9]. P. e1237
  7. Akinfiresoye L., Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR // Psychopharmacology [Berl]. 2013 Nov. Vol. 230[2]. P. 291-298
  8. Al-Harbi K.S. Treatment-resistant depression: therapeutic trends, challenges and future directions // Patient Prefer Adherence. 2012. Vol. 6. P. 369-388
  9. Aleksandrova L.R., Phillips A.G., Wang Y.T. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antago-nism // J Psychiatry Neurosci. 2017 Jan 31. Vol. 42[2]. P. 160-175
  10. Alonso-Serra H.M., Wesley K. Position paper for the National Association of EMS Physicians Standards and Clinical Practices Committee. Prehospital pain management // Prehospital Emergency Care. 2003. Vol. 7[4]. P. 482-488
  11. Anderson I.M., Blamire A., Branton T. et al. Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression [Ketamine-ECT study]. Southampton [UK]: NIHR Journals Library, 2017 Mar
  12. Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action // J Clin Psychiatry. 2017[a], Apr. Vol. 78[4]. P. e415-e419
  13. Andrade C. Ketamine for Depression, 2: Diagnostic and Contextual Indications // J Clin Psychiatry. 2017[b] May. Vol. 78[5]. P. e555-e558
  14. Andrade C. Ketamine for Depression, 3: Does Chirality Matter? // J Clin Psychiatry. 2017[c] Jun. Vol. 78[6]. P. e674-e677
  15. Andrade C. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? // J Clin Psychiatry. 2017[d] Jul. Vol. 78[7]. P. e852-e857
  16. Atigari O.V., Healy D. Sustained antidepressant response to ketamine // BMJ Case Reports, 2013
  17. Ballard E.D., Luckenbaugh D.A., Richards E.M. et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant // J Psychiatr Res. 2015 Sep. Vol. 68. P. 68-73
  18. Baumeister D., Barnes G., Giaroli G., Tracy D. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles // Therapeutic Advances in Psychopharmacology. 2014. Vol. 4[4]. P. 156-169
  19. Becker J. Regarding the Transpersonal Nature of Ketamine Therapy: An Approach to the Work. In: The Ketamine Papers: Science, Therapy, and Transformation. [Ed. by P. Wolfson and G. Hartelius] 2016 MAPS. P. 323-338
  20. Berman R.M., Cappiello A., Anand A. et al. Antidepressant effects of ketamine in depressed patients // Biol Psychiatry. 2000. Vol. 47. P. 351-354
  21. Björkenstam C., Moller J., Ringback G. et al. An association between initiation of selective serotonin reuptake inhibitors and suicide: A nationwide register-based case-crossover study // PLoS ONE. 2013. Vol. 8[9]. P. 73973
  22. Bokor G., Anderson P.D. Ketamine: an update on its abuse // J Pharm Pract. 2014 Dec. Vol. 27[6]. P. 582-586
  23. Bonnet U. Long-term ketamine self-injections in major depressive disorder: Focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction // Journal of Psychoactive Drugs. 2015. Vol. 47[4]. P. 276-285
  24. Caddy C., Amit B.H., McCloud T.L. et al. Ketamine and other glutamate receptor modulators for depression in adults // Cochrane Database Syst Rev. 2015 Sep. 23. Vol. 9. CD011612
  25. Can A., Zanos P., Moaddel R. et al. Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors and monoamine transporters // J Pharmacol Exp Ther. 2016 Oct. Vol. 359[1]. P. 159-170
  26. Chan K.W., Lee T.M., Siu A.M. et al. Effects of chronic ketamine use on frontal and medical temporal cognition // Addict Behav. 2013 May. Vol. 38[5]. P. 2128-2132
  27. Chilukuri H., Reddy N., Pathapati R. et al. Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine // Indian Psychol Med. 2014 Jan-Mar. Vol. 36[1]. P. 71-76
  28. Chong C., Schug S. A., Page-Sharp M. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain // Clinical Drug Investigation. 2009. Vol. 29[5]. P. 317-324
  29. Cipriani A., Furukawa T., Salanti G. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis // Lancet. 2018 Feb 20
  30. Conway C.R., Gebara M.A., Walker M.C. et al. Clinical characteristics and management of treatment-resistant depression // J Clini Psychiatry. 2015 Nov. Vol. 76[11]. P. 1569-1570
  31. Cooper M.D., Rosenblat J.D., Cha D. et al. Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: A narrative review // World Journal of Biological Psychiatry. 2017 Sep. Vol. 18[6]. P. 410-423
  32. Correll G.E., Futter G.E. Two case studies of patients with major depressive disorder given low-dose [subanesthetic] ketamine infusions // Pain Medicine. 2006. Vol. 7[1]. P. 92-95
  33. Covvey J.R., Crawford A.N., Lowe D.K. Intravenous ketamine for treatment-resistant major depressive disorder // Ann Pharmacother. 2012 Jan. Vol. 46[1]. P. 117-123
  34. Coyle C.M., Laws K.R. The use of ketamine as an antidepressant: a systematic review and meta-analysis // Hum Psychopharmacol. 2015 May. Vol. 30[3]. P. 152-163
  35. Cusin C., Ionescu D.F., Pavone K.J. et al. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation // J Psychiatry. 2017 Jan. Vo. 51[1]. P. 55-64
  36. da Frota Ribeiro C.M., Sanacora G., Hoffman R., Ostroff R. The use of ketamine for the treatment of depression in the context of psychotic symptoms: To the editor // Biological Psychiatry. 2016. Vol. 79[9]. P. e65-e66
  37. Dahmani S., Michelet D., Abback P.S. et al. Ketamine for perioperative pain management in children: a meta-analysis of published studies // Paediatr Anaesth. 2011 Jun. Vol. 21[6]. P. 636-652
  38. De Maricourt P., Jay T., Goncalvès P. et al. Ketamine’s antidepressant effect: literature review on clinical use // Encephale. 2014 Feb. Vol. 40[1]. P. 15-23
  39. Diamond P.R., Farmery A.D., Atkinson S. et al. Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic // Journal of Psychopharmacology. 2014. Vol. 28[6]. P. 536-544
  40. Diaz-Granados N., Ibrahim L., Brutsche N.E. et al. A randomized add-on trial of an N-methyl- D-aspartate antagonist in treatment-resistant bipolar depression // Archives of General Psychiatry. 2010 [а]. Vol. 67[8]. P. 793-802
  41. DiazGranados N., Ibrahim L.A., Brutsche N.E. et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder // J Clin Psychiatry. 2010 [b], Dec. Vol. 71[12]. P. 1605-1611
  42. Domino E. Taming the ketamine tiger // Anesthesiology. 2010. Vol. 113[3]. P. 678-684
  43. Dowben J.S., Grant J.S., Keltner N.L. Ketamine as an alternative treatment for treatment-resistant depression // Perspect Psychiatr Care. 2013 Jan. Vol. 49[1]. P. 2-4
  44. Drewniany E., Han J., Hancock C. et al. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression // J Clin Pharm Ther. 2015 Apr. Vol. 40[2]. P. 125-130
  45. du Jardin K.G., Müller H.K., Elfving B. et al. Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: A critical review // Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3. Vol. 71. P. 27-38
  46. Duman R.S. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections // Dialogues Clin Neurosci. 2014 Mar. Vol 16[1]. P. 11-27
  47. Duman R.S., Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists // Philos Trans R Soc Lond B Biol Sci. 2012. Vol. 367. P. 2475-2484
  48. Early T.S. Making ketamine work in the long run // International Journal of Transpersonal Studies. 2014. Vol. 33[2]. P. 141-150
  49. Edward Roberts R., Curran H.V., Friston K.J., Morgan C.J. Abnormalities in white matter microstructure associated with chronic ketamine use // Neuropsychopharmacology. 2014 Jan. Vol. 39[2]. P. 329-338
  50. Feder A., Parides M.K., Murrough J.W. et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial // JAMA Psychiatry. 2014. Vol. 71[6]. P. 681-688
  51. Finke C., Kopp U.A., Prüss H. et al. Cognitive deficits following anti-NMDA receptor encephalitis // J Neurol Neurosurg Psychiatry. 2012 Feb. Vol. 83[2]. P. 195-198
  52. Fond G., Boyer L. Ketamine vs other anesthetic agents for electroconvulsive therapy [ECT] in major depression // J Psychiatr Res. 2015 Sep. Vol. 68. P. 226-227
  53. Fond G., Loundou A., Rabu C. et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis // Psychopharmacology [Berl]. 2014 Sep. Vol. 231[18]. P. 3663-3676
  54. Fontana A. Terapia antidpresiva con Ci 581 [ketamine] // Acta Psiquiatrica Y Psicologica de America Latina. 1974. Vol. 4. P. 20-32
  55. Gálvez V., O’Keefe E., Cotiga L. et al. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: A case report // Biological Psychiatry. 2014. Vol. 76[3]. P. e1-e2
  56. Gaynes B.N., Warden D., Trivedi M.H. et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression // Psychiatr Serv. 2009. Vol. 60. P. 1439-1445
  57. Ghasemi M., Kazemi M.H., Yoosefi A. et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder // Psychiatry Res. 2014 Feb 28. Vol. 215[2]. P. 355-361
  58. Giorgetti R., Marcotulli D., Tagliabracci A., Schifano F. Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability // Forensic Sci Int. 2015 Jul. Vol. 252. P. 127-142
  59. Gosek P., Chojnacka M., Bieńkowski P., Swiecicki Ł. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy] // Psychiatr Pol. 2014 Jan-Feb. Vol. 48[1]. P. 49-58
  60. Gourion D. [Antidepressants and their onset of action: a major clinical, methodological and prognostical issue] // Encephale. 2008 Jan. Vo. 34[1]. P. 73-81
  61. Gutstein H.B. Potential physiologic mechanism for ketamine-induced emergence delirium // Anesthesiology. 1996 Feb. Vol. 84[2]. P. 474
  62. Hartberg J., Garrett-Walcott S., De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study // Psychopharmacology [Berl]. 2018 Feb. Vol. 235[2]. P. 393-398
  63. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder // Brain Research Reviews. 2009. Vol. 61. P. 105-123
  64. Hassamal S., Spivey M., Pandurangi A.K. Augmentation therapy with serial intravenous ketamine over 18 months in a patient with treatment resistant depression // Clinical Neuropharmacology. 2015. Vol. 38[5]. P. 212-216
  65. Henter I.D., de Sousa R.T., Zarate C.A.Jr. Glutamatergic Modulators in Depression // Harv Rev Psychiatry. 2018 Feb 20
  66. Hillhouse T.M., Porter J.H. A brief history of the development of antidepressant drugs: from monoamines to glutamate // Exp Clin Psychopharmacol. 2015 Feb. Vol. 23[1]. P. 1-21
  67. Howland R.H. Ketamine for the treatment of depression // J Psychosoc Nurs Ment Health Serv. 2013 Jan. P. 51[1]. P. 11-44
  68. Hu Y.D., Xiang Y.T., Fang J.X. et al. Single IV ketamine augmentation of newly initiated escitalopram for major depression: Results from a randomized, placebo-controlled 4-week study // Psychological Medicine. 2016. Vol. 46[3]. P. 623-635
  69. Hyde S. Sustainable Ketamine Therapy: An Overview of Where We are and Where We May Go. In: The Ketamine Papers: Science, Therapy, and Transformation. [Ed. by P. Wolfson and G. Hartelius], 2016 MAPS. P. 275-290
  70. Ibrahim L., Diaz-Granados N., Jolkovsky L. et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder // Journal of Clinical Psychopharmacology. 2012. Vol. 32[4]. P. 551-557
  71. Ibrahim L., Diaz-Granados N., Luckenbaugh D.A. et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression // Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2011. Vol. 35[4]. P. 1155-1159
  72. Iglewicz A., Morrison K., Nelesen R.A. et al. Ketamine for the treatment of depression in patients receiving hospice care: A retrospective medical record review of thirty-one cases // Psychosomatics. 2015 Jul-Aug. Vol. 56[4]. P. 329-337
  73. Ionescu D.F., Felicione J.M., Gosai A. et al. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature // Harv Rev Psychiatry. 2018 Feb 20
  74. Ionescu D.F., Luckenbaugh D.A., Niciu M.J. et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine // J Clin Psychiatry. 2014 Sep. Vol. 75[9]. P. e932-938
  75. Ionescu D.F., Swee M.B., Pavone K.J. et al. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study // J Clin Psychiatry. 2016 Jun. Vol. 77[6]. P. e719-725
  76. Irwin S.A., Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care // J Palliat Med. 2010 Jul. Vol. 13[7]. P. 903-908
  77. Jaitly V. K. Sublingual ketamine in chronic pain: Service evaluation by examining more than 200 patient years of data // Journal of Observational Pain Medicine. 2013. Vol. 1[2]
  78. Jansen K. A review of the non-medical use of ketamine: Use, users and consequences // Journal of Psychoactive Drugs. 2000. Vol. 32[4]. P. 419-433
  79. Jansen K. Ketamine: Dreams and realities. Sarasota, 2001 FL: MAPS
  80. Jansen K., Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence // J Psychoactive Drugs. 2001. Vol. 33[2]. P. 151-158
  81. Jaso B.A., Niciu M.J., Iadarola N.D. et al Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder // Curr Neuropharmacol. 2017. Vol. 15[1]. P. 57-70
  82. Jennings P.A., Cameron P., Bernard S. Ketamine as an analgesic in the pre-hospital setting: A systematic review // Acta Anaesthesia Scandanavia. 2011. Vol. 55. P. 638-643
  83. Jick H., Kaye J.A., Jick S.S. Antidepressants and the risk of suicidal behaviors // JAMA. 2004 Jul 21. Vol. 292[3]. P. 338-343
  84. Johnson M.W., Richards W.A., Griffiths R.R. Human hallucinogen research: guidelines for safety // Journal of Psychopharmacology. 2008. Vol. 22[6]. P. 603-620
  85. Kantrowitz J.T., Halberstam B., Gangwisch J. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression // Journal of Clinical Psychiatry. 2015. Vol. 76[6]. P. 737-738
  86. Kaplan A. New claims and findings for ketamine in severe depression // Psychiatric Times. 2013. Vol. 1. P. 1-10
  87. Katalinic N., Lai R., Somogyi A. et al. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects // J Psychiatry. 2013 Aug. Vol. 47[8]. P. 710-727
  88. Kavalali E.T., Monteggia L.M. How does ketamine elicit a rapid antidepressant response? // Curr Opin Pharmacol. 2015 Feb. Vol. 20. P. 35-39
  89. Kavalali E.T., Monteggia L.M. Synaptic mechanisms underlying rapid antidepressant action of ketamine // Am J Psychiatry. 2012 Nov. Vol. 169[11]. P. 1150-1156
  90. Kendell S.F., Krystal J.H., Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders // Expert Opin Ther Targets. 2005 Feb. 9[1]. P. 153-168
  91. Khorramzadeh E., Lofty A. Personality predisposition and emergence phenomena with ketamine // Psychosomatics. 1976. Vol. 17[2]. P. 94-95
  92. Khorramzadeh E., Lofty A. The use of ketamine in psychiatry // Psychosomatics. 1973. Vol. 14[6]. P. 344-346
  93. Kishimoto T., Chawla J.M., Hagi K. et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories // Psychol Med. 2016 May. Vol. 46[7]. P. 1459-1472
  94. Köhler S., Betzler F. [Ketamine - a new treatment option for therapy-resistant depression] // Fortschr Neurol Psychiatr. 2015 Feb. Vol. 83[2]. P. 91-97
  95. Kolp E., Friedman H.L., Krupitsky E. et al. Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology and clinical applications // International Journal of Transpersonal Studies. 2014. Vol. 33[2]. P. 84-140
  96. Krupitsky E. Ketamine psychedelic therapy [KPT] of alcoholism and neurosis. Yearbook of the European College for the Study of Consciousness, 1993/1994. P. 113-122
  97. Kudoh A., Takahira Y., Katagai H., Takazawa T. Small dose ketamine improves the postoperative state of depressed patients // Anesthesia and Analgesia. 2002. Vol. 95. P. 114-118
  98. Kwon J.H., Sim W.S., Hong J.P. et al. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up // J Clin Pharm Ther. 2018 Jan 25
  99. Lai R., Katalinic N., Glue P. et al. Pilot dose-response trial of IV ketamine in treatment-resistant depression // World Journal of Biological Psychiatry. 2014. Vol. 15[7]. P. 579-584
  100. Lally N., Nugent A.C., Luckenbaugh D.A. et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression // Transl Psychiatry. 2014 Oct 14. Vol. 4. P. e469
  101. Lally N., Nugent A.C., Luckenbaugh D.A. et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine // J Psychopharmacol. 2015 May. Vol. 29[5]. P. 596-607
  102. Lapidus K.A., Levitch C.F., Perez A.M. et al. A randomized controlled trial of intranasal ketamine in major depressive disorder // Biol Psychiatry. 2014 Dec 15. Vol. 76[12]. P. 970-976
  103. Lee Y., Syeda K., Maruschak N.A. et al. A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect // J Clin Psychopharmacol. 2016 Feb. Vol. 36[1]. P. 50-56
  104. Lenze E.J., Farber N.B., Kharasch E. et al. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial // World J Biol Psychiatry. 2016 Apr. Vol. 17[3]. P. 230-238
  105. Levine S. Intravenous Ketamine. In: The Ketamine Papers: Science, Therapy, and Transformation. [Ed. by P. Wolfson and G. Hartelius], 2016 MAPS. P. 291-304
  106. Li C.T., Chen M.H., Lin W.C. et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study // Hum Brain Mapp. 2016 Mar. [3]. P. 1080-1090
  107. Li J.H., Vicknasingam B., Cheung Y.W. et al. To use or not to use: an update on licit and illicit ketamine use // Subst Abuse Rehabil. 2011. Vol. 2. P. 11-20
  108. Liao Y., Tang J., Ma M. et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging stud // Brain. 2010 Jul. Vol. 133[Pt 7]. P. 2115-2122
  109. Lim D. Ketamine associated psychedelic effects and dependence // Singapore Medical Journal. 2003. Vol. 44[1]. P. 31-34
  110. Lin C.H., Huang Y.J., Lin C.J. et al. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease // Curr Pharm Des. 2014. Vol. 20[32]. P. 5169-5179. Review
  111. Loo C. Can we confidently use ketamine as a clinical treatment for depression? // Lancet Psychiatry. 2018 Jan. Vol. 5[1]. P. 11-12
  112. Loo C.K., Gálvez V., O’Keefe E. et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression // Acta Psychiatrica Scandinavica. 2016. Vol. 134[1]. P. 48-56
  113. López-Díaz Á., Fernández-González J.L., Luján-Jiménez J.E. et al. Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain // Ther Adv Psychopharmacol. 2017 Apr. Vol. 7[4]. P. 137-140
  114. López-Muñoz F., Alamo C. Monoaminergic neurotrans-mission: the history of the discovery of antidepressants from 1950s until today // Curr Pharm Des. 2009. Vol. 15[14]. P. 1563-1586
  115. Luckenbaugh D. A., Ibrahim L., Brutsche N. et al. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression // Bipolar Disorders. 2012. Vol. 14[8]. P. 880-887
  116. Luckenbaugh D.A., Niciu M.J., Ionescu D.F. et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? // Journal of Affective Disorders, 2014. Vol. 159. P. 56-61
  117. Machado-Vieira R., Manji A., Zarate C. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders // Neuroscientist. 2009. Vol. 15. P. 525-539
  118. Maeng S., Zarate C.A.Jr., Du J. et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors // Biological Psychiatry. 2008. Vol. 63[4]. P. 349-352
  119. Maeng S., Zarate C.A.Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects // Current Psychiatry Reports. 2007. Vol. 9[6]. P. 467-474
  120. Majić T., Schmidt T.T., Gallinat J. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? // J Psychopharmacol. 2015 Mar. Vol. 29[3]. P. 241-253
  121. Malhi G.S., Byrow Y., Cassidy F. et al. Ketamine: stimulating antidepressant treatment? // BJPsych Open. 2016 May 11. Vol. 2[3]. P. e5-e9
  122. Manji H.K., Quiroz J.A., Sporn J. et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression // Biol Psychiatry. 2003. Vol. 53. P. 707-742
  123. Mason O.J., Morgan C.J. M., Stefanovic A., Curran H.V. The Psychotomimetic States Inventory [PSI]: Measuring psychotic-type experiences from ketamine and cannabis // Schizophrenia Research. 2008. Vol. 103. P. 138-142
  124. Mathew S., Murrough J., aan het Rot M. et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial // International Journal of Neuropsychopharmacology. 2010. Vol. 13. P. 71-82
  125. Mathew S.J., Shah A., Lapidus K. et al. Ketamine for treatment-resistant unipolar depression: current evidence // CNS Drugs. 2012 Mar 1. Vol. 26[3]. P. 189-204
  126. McCloud T.L., jardi C., Jochim J. et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults // Cochrane Database Syst Rev. 2015 Sep 29. [9]:CD011611
  127. McGirr A., Berlim M.T., Bond D.J. et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes // Psychol Med. 2015 Mar. Vol. 45[4]. P. 693-704
  128. Mills I.H., Park G.R., Manara A.R., Merriman R.J. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions // QJM: An International Journal of Medicine. 1998. Vol. 91[7]. P. 493-503
  129. Monteggia L.M., Gideons E., Kavalali E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine // Biological Psychiatry. 2013. Vol. 73[12]. P. 1199-1203
  130. Monteggia L.M., Zarate C.Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice // Curr Opin Neurobiol. 2015 Feb. Vol. 30. P. 139-143
  131. Moore N., Bostwick J. Ketamine dependence in anesthesia providers // Psychosomatics. 1999. Vol. 40[4]. P. 356-359
  132. Morgan C., Curran H. Ketamine use: A review // Addiction. 2012. Vol. 107[1]. P. 27-38
  133. Morgan C., Muetzelfeldt L., Curran H. Ketamine use, cognition and psychological wellbeing: A comparison of frequent, infrequent and ex-users with polydrug and non-using controls // Addiction. 2009. Vol. 104[1]. P. 77-87
  134. Morgan C.J., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study // Addiction. 2010 Jan. Vol. 105[1]. P. 121-133
  135. Murrough J., Perez A., Pillemer S. et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression // Biological Psychiatry. 2012. Vol. 74[4]. P. 250-256
  136. Murrough J.W., Burdick K.E., Levitch C.F. et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: A randomized controlled trial // Neuropsychopharmacology. 2015. Vol. 40[5]. P. 1084-1090
  137. Musazzi L., Treccani G., Mallei A., Popoli M. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors //Biol Psychiatry. 2013 Jun 15. Vol. 73[12]. P. 1180-1188
  138. Myers K.M., Carlezon W.A., Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness // Neuropsychopharmacology. 2011. Vol. 36. P. 274-293
  139. Naughton M., Clarke G., O’Leary O.F. et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action // J Affect Disord. 2014 Mar. Vol. 156. P. 24-35
  140. Newport D.J., Carpenter L.L., McDonald W.M. et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression // Am J Psychiatry. 2015 Oct. Vol. 172[10]. P. 950-966
  141. Ng S.H., Tse M.L., Ng H.W., Lau F.L. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases // Hong Kong Med J. 2010 Feb. Vol. 16[1]. P. 6-11
  142. Nguyen L., Marshalek P.J., Weaver C.B. et al. Off-label use of transmucosal ketamine as a rapid acting antidepressant: A retrospective chart review // Journal of Neuropsychiatric Disease and Treatment. 2015. Vol. 11. P. 2667-2673
  143. Niciu M.J., Luckenbaugh D.A., Ionescu D.F. et al. Ketamine’s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder // Int J Neuropsychopharmacol. 2014 Oct 31. Vol. 18[1]
  144. Niciu M.J., Shovestul B.J., Jaso B.A. et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression // J Affect Disord. 2018 Feb 17. Vol. 232. P. 310-315
  145. Nikiforuk A. Popik P. Ketamine prevents stress-induced cognitive inflexibility in rats // Psychoneuroendocrinology. 2014 Feb. Vol. 40. P. 119-122
  146. Nugent A.C., Diazgranados N., Carlson P.J. et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder // Bipolar Disord. 2014 Mar. Vol. 16[2]. P. 119-128
  147. Pałucha-Poniewiera A., Pilc A. Glutamate-Based Drug Discovery for Novel Antidepressants // Expert Opin Drug Discov. 2016 Sep. Vol. 11[9]. P. 873-883
  148. Paslakis G., Gass P., Deuschle M. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data] // Fortschr Neurol Psychiatr. 2011 Apr. Vol. 79[4]. P. 204-212
  149. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies // Ann N Y Acad Sci. 2003 Nov. Vol. 1003. P. 250-272
  150. Pennybaker S.J., Niciu M.J., Luckenbaugh D.A., Zarate C.A. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion // J Affect Disord. 2017 Jan 15. Vol. 208. P. 560-566
  151. Pereira V.S., Hiroaki-Sato V.A. A brief history of anti-depressant drug development: from tricyclics to beyond ketamine // Acta Neuropsychiatr. 2018 Feb 1. P.1-16
  152. Pettinati H.M., O’Brien C.P., Dundon W.D. Current status of co-occurring mood and substance use disorders: a new therapeutic target // Am J Psychiatry. 2013 Jan. Vol.170[1]. P. 23-30
  153. Phelps L.E., Brutsche N., Moral J.R. et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist // Biological Psychiatry. 2009. Vol. 65[2]. P. 181-184
  154. Pilc A., Wierońska J.M., Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology // Biol Psychiatry. 2013 Jun 15. Vol. 73[12]. P. 1125-1132
  155. Price R.B., Iosifescu D.V., Murrough J.W. et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression // Depress Anxiety. 2014 Apr. Vol. 31[4]. P. 335-343
  156. Prommer E.E. Ketamine for pain: An update of uses in palliative care // Journal of Palliative Medicine. 2012. Vol. 15[4]. P. 474-483
  157. Raffa R.B., Pergolizzi J.V. Jr., Taylor R Jr.; NEMA Research Group. The rapid-onset antidepressant effect of ketamine: More surprises? // J Clin Pharm Ther. 2018 Apr. Vol. 43[2]. P. 308-311
  158. Rasmussen K., Lineberry T., Galardy C. et al. Serial infusions of low-dose ketamine for major depression // Journal of Psychopharmacology. 2013. Vol. 27[5]. P. 444-450
  159. Reid I.C., Stewart C.A. How antidepressants work: new perspectives on the pathophysiology of depressive disorder // Br J Psychiatry. 2001. Vol. 178. P. 299-303
  160. Rodriguez C.I., Kegeles L.S., Levinson A. et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept // Neuropsychopharmacology. 2013. Vol. 38[12]. P. 2475-2483
  161. Rush A.J., Trivedi M.H., Wisniewski S.R. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report // Am J Psychiatry. 2006. Vol. 163. P. 1905-1917
  162. Ryan W.C., Marta C.J., Koek R.J. Ketamine, Depression, and Current Research: A Review of the Literature. In: The Ketamine Papers: Science, Therapy, and Transformation. [Ed. by P. Wolfson and G. Hartelius], 2016 MAPS. P. 199-273
  163. Sanacora G., Frye M.A., McDonald W. et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. American Psychiatric Association [APA] Council of Research Task Force on Novel Biomarkers and Treatments // JAMA Psychiatry. 2017 Apr 1. Vol. 74[4]. P. 399-405
  164. Sanacora G., Heimer H., Hartman D. et al. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders // Neuropsychopharmacology. 2017 May. Vol. 42[6]. P. 1179-1181
  165. Sanacora G., Kendell S., Levin Y. et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms // Biological Psychiatry. 2007. Vol. 61[6]. P. 822-825
  166. Sanacora G., Schatzberg A. Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? // Neuropsychopharmacology. 2015. Vol. 40. P. 259-267
  167. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders // Neuropharmacology. 2012 Jan. Vol. 62[1]. P. 63-77
  168. Sassano-Higgins S., Baron D., Juarez G. et al. A review of ketamine abuse and diversion // Depress Anxiety. 2016 Aug. Vol. 33[8]. P. 718-727
  169. Schoevers R.A., Chaves T.V., Balukova S.M. et al. Oral ketamine for the treatment of pain and treatment-resistant depression // Br J Psychiatry. 2016 Feb. Vol. 208[2]. P. 108-113
  170. Serafini G., Howland R.H., Rovedi F. et al. The role of ketamine in treatment-resistant depression: a systematic review // Curr Neuropharmacol. 2014 Sep. Vol. 12[5]. P. 444-461
  171. Shahani R., Streutker C., Dickson B., Stewart R.J. Ketamine-associated ulcerative cystitis: A new clinical entity // Urology. 2007. Vol. 69[5]. P. 810-812
  172. Shiroma P.R., Johns B., Kuskowski M. et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression // J Affect Disord. 2014 Feb. Vol. 155. P. 123-129
  173. Short B., Fong J., Galvez V. et al. Side-effects associated with ketamine use in depression: a systematic review // Lancet Psychiatry. 2018 Jan. Vol. 5[1]. P. 65-78
  174. Singh I., Morgan C., Curran V. et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight // Lancet Psychiatry. 2017 May. Vol. 4[5]. P. 419-426
  175. Singh J.B., Fedgchin M., Daly E.J. et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous кetamine in patients with treatment-resistant depression // Am J Psychiatry. 2016 Aug 1. Vol. 173[8]. P. 816-826
  176. Skolnick P. Modulation of glutamate receptors: strategies for the development of novel antidepressants // Amino Acids. 2002. Vol. 23. P. 153-159
  177. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on // Trends in Pharmacological Science. 2009. Vol. 30. P. 563-569
  178. Slikker W., Zou X., Hotchkiss C. et al. Ketamine-induced neuronal cell death in the perinatal rhesus monkey // Toxicological Sciences. 2007. Vol. 98[1]. P. 145-158
  179. Sos P., Klirova M., Novak T. et al. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression // Neuro Endocrinol Lett. 2013. Vol. 34[4]. P. 287-293
  180. Strasburger S.E., Bhimani P.M., Kaabe J.H. et al. What is the mechanism of ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibi- lities // J Clin Pharm Ther. 2017 Apr. Vol. 42[2]. P. 147-154
  181. Strayer R.J., Nelson L.S. Adverse events associated with ketamine for procedural sedation in adults // The American Journal of Emergency Medicine. 2008. Vol. 26[9]. P. 985-1028
  182. Sun L., Li Q., Zhang Y., Liu D. et al. Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys // Addiction Biology. 2014. Vol. 19[2]. P. 185-194
  183. Szymkowicz S.M., Finnegan N., Dale R.M. Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder // Journal of Clinical Psychopharmacology. 2014. Vol. 34[2]. P. 285-286
  184. Tolliver B.K., Anton R.F. Assessment and treatment of mood disorders in the context of substance abuse // Dialogues Clin Neurosci. 2015 Jun. Vol. 17[2]. P. 181-190
  185. Trevithick L., McAllister-Williams R.H. Blamire A. et al. Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression [Ketamine-ECT study] // BMC Psychiatry. 2015 Oct 21. Vol. 15. P. 257
  186. Valentine G., Mason G., Gomez R. et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [[1]H]-MRS // Psychiatry Research Neuroimaging. 2011. Vol. 191. P. 122-127
  187. Vande Voort J.L., Morgan R.J., Kung S. et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression // J Affect Disord. 2016 Dec. Vol. 206. P. 300-304
  188. Wilkinson S.T., Ballard E.D., Bloch M.H. et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis // Am J Psychiatry. 2018 Feb 1. Vol. 175[2]. P. 150-158
  189. Wilkinson S.T., Wright D., Fasula M.K. et al. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression // Psychother Psychosom. 2017. Vol. 86[3]. P. 162-167
  190. Wink L.K., O’Melia A.M., Shaffer R.C. et al. Intranasal ketamine treatment in an adult with autism spectrum disorder // J Clin Psychiatry. 2014 Aug. Vol. 75[8]. P. 835-836
  191. Winstock A. R., Mitcheson L., Gillatt D. A., Cottrell A. M. The prevalence and natural history of urinary symptoms among recreational ketamine users // BJU International. 2012. Vol. 110. P. 1762-1766
  192. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders // CNS Neurol Disord Drug Targets. 2007 Apr. Vol. 6[2]. P. 87-100
  193. Wolfson P. Ketamine: Consciousness and Transformation. Multidisciplinary //In The Ketamine Papers: Science, Therapy and Transformation. /Ed. by P. Wolfson and G. Hartelius, 2016 MAPS, 390 p
  194. Wu P., Wang Q., Huang Z. et al., Clinical staging of ketamine-associated urinary dysfunction: A strategy for assessment and treatment // World Journal of Urology. 2016. Vol. 34. P. 1329-1336
  195. Xu J., Lei H. Ketamine-an update on its clinical uses and abuses // CNS Neurosci Ther. 2014 Dec. Vol. 20[12]. P. 1015-1020
  196. Yensen R. From mysteries to paradigms: Humanity’s journey from sacred plants to psychedelic drugs // ReVision. 1985. Vol. 10[4]. P. 31-50
  197. Zanos P. Moaddel R., Morris P.J. et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites // Nature. 2016. Vol. 533. P. 481-486
  198. Zarate C., Singh J., Carlson P.et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression // Archives of General Psychiatry. 2006. Vol. 63. P. 856-864
  199. Zarate C.A., Brutsche N.E., Ibrahim L. et al. Replication of ketamine’s antidepressants efficacy in bipolar depression: A randomized controlled add-on trial // Biological Psychiatry. 2012. Vol. 71. P. 939-946
  200. Zarate C.A., Mathews D., Ibrahim L. et al. A randomized trial of a low-trapping non-selective N-methyl-D-aspartate channel blocker in major depression // Biological Psychiatry. 2013. Vol. 74[4]. P. 257-264
  201. Zarate C.A. Jr., Du J., Quiroz J. et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system // Ann N Y Acad Sci. 2003 Nov. Vol. 1003. P. 273-291
  202. Zhang M., Rosenheck R., Lin X. et al. A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression // J Affect Disord. 2018 Feb. Vol. 227. P. 372-378
  203. Zhang M.W., Harris K.M., Ho R.C. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns and legal implications // BMC Med Ethics. 2016 Jan 14. Vol. 17. P. 4
  204. Zhang M.W., Hong Y.X., Husain S.F. et al. Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015 // PLoS ONE. 2017. Vol. 12[3]. P. e0173202
  205. Zhou W., Wang N., Yang C. et al. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex // Eur Psychiatry. 2014 Sep. Vol. 29[7]. P. 419-423
  206. Zhu W., Ding Z., Zhang Y. et al. Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant // Neurosci Bull. 2016 Dec. Vol. 32[6]. P. 557-564
  207. Zigman D., Blier P. Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: A case report // Journal of Clinical Psychopharmacology. 2013. Vol. 33[2]. P. 270-272
  208. Zorumski C.F., Izumi Y., Mennerick S. Ketamine: NMDA Receptors and Beyond // J Neurosci. 2016 Nov 2. Vol. 36[44]. P. 11158-11164

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Zobin M.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».